Saturday, July 19, 2025 7:02:12 PM
Your claim that the EDEN unit “hasn’t even been built yet” and is “obviously not in the MAA” is flatly contradicted by NWBO’s own SEC disclosures.
From the 2025 10-K:
“We are continuing comparability testing between the products manufactured manually and the products manufactured using the Flaskworks system, in connection with the anticipated inclusion of the Flaskworks system in our regulatory applications.”
That is not speculative. That is an explicit statement of regulatory intent, worded precisely, submitted under SEC oversight, and built around an active integration plan.
From the Q1 2025 10-Q:
“We are also continuing integration of the Flaskworks EDEN system at our manufacturing site, and preparing for additional regulatory filings and inspections relating to this system.”
Integration. Inspections. Regulatory filings. These are not future ideas. They’re active processes, in motion, and reflected in formal documents governed by securities law.
This isn’t just a contradiction of your claim, it’s a directional signal. NWBO is either including Flaskworks in the current MAA or staging it for immediate post-approval deployment under a defined regulatory pathway. That’s not up for interpretation. It’s spelled out in plain language.
You also ignore that MHRA publicly disclosed inspections of U.S. manufacturing sites in 2024. DCVax-L is manufactured in the UK. There is no plausible reason for MHRA to be inspecting U.S. facilities unless Flaskworks was involved. That inspection trail aligns with the SEC disclosures and further confirms its regulatory relevance.
SI 2025 No. 87 is now in force. It creates a legal infrastructure for Control Site licensing, modular GMP systems, and named-patient labeling. The EDEN unit fits that structure with precision. That legislation didn’t appear in a vacuum. It was written to accommodate something specific.
No speculation required. The disclosures speak for themselves
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
